Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled...

Area of Science:

• Reproductive Health
• Pharmacology
• Obesity Medicine

Background:

• Individuals with obesity and higher body mass index (BMI) face increased risks of emergency contraception failure with levonorgestrel (LNG).
• Altered pharmacokinetic profiles in individuals with obesity may affect LNG efficacy.

Purpose of the Study:

• To evaluate if escalating the dose of levonorgestrel (LNG) emergency contraception improves pharmacodynamic outcomes in individuals with obesity.
• To determine if a doubled dose of LNG is more effective in preventing ovulation or delaying follicle rupture in this population.

Main Methods:

• A randomized pharmacodynamic study enrolled healthy, reproductive-age individuals with BMI > 30 and weight ≥ 176 lbs.
• Participants received either 1.5 mg or 3 mg (double dose) of oral LNG emergency contraception after ovulation confirmation.
• Daily monitoring via transvaginal ultrasonography and blood sampling tracked hormonal changes and follicle development for up to 7 days post-dosing.

Main Results:

• No significant difference was observed in the proportion of participants without follicle rupture more than 5 days post-dosing between the 1.5 mg (51.4%) and 3 mg (68.6%) LNG groups (P=.14).
• The time to follicle rupture did not differ between the groups for those experiencing rupture before 5 days.

Conclusions:

• A simple strategy of doubling the levonorgestrel dose does not appear to be an effective intervention to improve emergency contraception outcomes in individuals with obesity.
• Further research may be needed to explore alternative strategies for effective emergency contraception in this demographic.